CD274 and endometrial cancer: Overall, targeting PD-1/PD-L1 in endometrial cancer seems to be a promising therapeutic strategy to not only target cancer cells, but also CSCs with considerable anti-tumor effects to improve clinical outcomes and prevent cancer recurrence.